Clinical Trial

Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)

Study acronym: GALILEO
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 31, 2024 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The scope of GALILEO project (Genomic ALteratIons and cLonal EvOlution in ALK+ NSCLC) is to explore the feasibility of genomic longitudinal evaluation for ALK+ NSCLC patients in Italian routine practice and provide a detailed overview of resistance mechanisms and clinical outcomes according to current standard treatments.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06234579
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions ALK Gene Mutation, NSCLC Stage IV, ALK Sensitizing Mutation
Enrollment 108 participants
Start Date 2021-07-12
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-31